Epigenomics AG risk profile
85 Acute at or past the historical limit
Measured 21 October 2026 from ECX.F's filed statements. Recomputed nightly.
85 (Acute), driven by Competitive position at 100, over 3 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 79 | Stretched | Stable | Drawdown from the 52-week high — 41.6% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | Reads operating_cashflow, capital_expenditure, free_cashflow, net_income and revenue. No reading is stored for this company. | |||
| Leverage and coverage | 45 | Elevated | Stable | Net debt to EBITDA |
| Competitive position | 100 | Acute | Stable | Operating-margin gap against peers — -1,245.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.